PMID- 33709168
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20210611
IS  - 1435-1250 (Electronic)
IS  - 0340-1855 (Linking)
VI  - 80
IP  - 5
DP  - 2021 Jun
TI  - Anti-TNF-alpha-induced lupus syndrome : Two case reports and review of current 
      literature.
PG  - 481-486
LID - 10.1007/s00393-021-00983-8 [doi]
AB  - Anti-tumor necrosis factor‑alpha (TNF-alpha)-induced lupus (ATIL) represents a diagnostic 
      and treatment challenge. Most cases are caused by infliximab and in some cases by 
      etanercept and adalimumab. Symptoms can range from cutaneous manifestations to 
      more rare and serious conditions. Diagnosis requires a temporal relationship 
      between symptoms and positive autoantibody determination. Arthritis and cutaneous 
      symptoms are the most common manifestations accompanied by positive antinuclear 
      antibody (ANA) and anti-double strand DNA (dsDNA) determinations. The etiology of 
      ATILS remains to be definitively established. Several mechanisms have been 
      proposed for anti-TNF-alpha-induced lupus, including apoptosis, immunosuppression and 
      humoral autoimmunity. Treatment includes discontinuation of anti-TNF‑alpha agents and 
      in some cases corticosteroids and immunosuppressors. Questions to be answered: 
      (1) Are soluble TNF receptor fusion proteins such as etanercept and anti-TNF 
      chimeric antibodies equally likely to cause ATIL? (2) Can patients with ATIL 
      switch from one anti-TNF‑alpha antagonist to another? (3) Can the concurrent use of 
      a conventional synthetic disease-modifying antirheumatic drug (csDMARD) like 
      methotrexate or hydroxychloroquine reduce the probability of ATIL?
FAU - Sieiro Santos, Cristiana
AU  - Sieiro Santos C
AD  - Rheumatology Department, Complejo Asistencial Universitario de Leon, Calle Altos 
      de nava, s/n, 24001, Leon, Spain. cristysieirosantos@gmail.com.
FAU - Alvarez Castro, Carolina
AU  - Alvarez Castro C
AD  - Rheumatology Department, Complejo Asistencial Universitario de Leon, Calle Altos 
      de nava, s/n, 24001, Leon, Spain.
FAU - Moriano Morales, Clara
AU  - Moriano Morales C
FAU - Diez Alvarez, Elvira
AU  - Diez Alvarez E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
TT  - Anti-TNF-alpha-induziertes Lupussyndrom : Ubersicht uber die aktuelle Literatur und 
      2 Kasuistiken.
DEP - 20210311
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab
MH  - Antibodies, Monoclonal
MH  - *Antirheumatic Agents/adverse effects
MH  - Etanercept/adverse effects
MH  - Humans
MH  - *Tumor Necrosis Factor Inhibitors
MH  - Tumor Necrosis Factor-alpha
OTO - NOTNLM
OT  - Adalimumab
OT  - Anti-tumor necrosis factor‑alpha induced lupus
OT  - Drug-induced lupus
OT  - Etanercept
OT  - Infliximab
EDAT- 2021/03/13 06:00
MHDA- 2021/06/12 06:00
CRDT- 2021/03/12 07:26
PHST- 2021/02/12 00:00 [accepted]
PHST- 2021/03/13 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
PHST- 2021/03/12 07:26 [entrez]
AID - 10.1007/s00393-021-00983-8 [pii]
AID - 10.1007/s00393-021-00983-8 [doi]
PST - ppublish
SO  - Z Rheumatol. 2021 Jun;80(5):481-486. doi: 10.1007/s00393-021-00983-8. Epub 2021 
      Mar 11.